Beranda › Artritis Psoriatik › Georgia
Uji klinis Artritis Psoriatik di Georgia
7 studi untuk Artritis Psoriatik mencari peserta di lokasi di Georgia.
Teks studi resmi (Bahasa Inggris)
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
Menerima pesertaFase 3
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06663332A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
- Atlanta Research Center for Rheumatology, Marietta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07321873A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- Marietta Rheumatology Associates, Marietta
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06671483Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- Clinical Site, Gainesville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06641089A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
- North Georgia Rheumatology Group PC, Lawrenceville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06671496Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
- Emory Children's Center, Atlanta
- Georgia Regents University Medical Center, Augusta
Menerima pesertaStudi observasional
Hingga usia 21 · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT02418442Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- Parris and Associates, Lilburn
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 9 Okt 2025 · NCT05669833Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.